A Study of IBI362 in Chinese Patients With Type 2 Diabetes

NCT04965506 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication IBI362 in Chinese adults with type 2 diabetes to see how it affects their blood sugar levels over 20 weeks.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 252 people

Who can join Ages 18–75 · all sexes

Timeline Started 2021-09 · est. completion 2022-06

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT04965506 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate the efficacy and safety of IBI362 in Chinese patients with Type 2 Diabetes.

Treatments tested

IBI362 Drug

IBI362 administered subcutaneously (SC) once a week.
placebo Other

placebo administered subcutaneously (SC) once a week.
Dulaglutide Other

Dulaglutide administered subcutaneously (SC) once a week.

Main thing measured	The change in HbA1c from baseline to 20 weeks
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04965506 ↗